(Q30310243)

16 June 2017

1 reference

title

Economic outcomes of the obese patient (English)

1 reference

16 June 2017

0 references

1 reference

Anne M Wolf

1

1 reference

16 June 2017

1 November 2002

1 reference

16 June 2017

1 reference

16 June 2017

10 Suppl 1

1 reference

16 June 2017

58S-62S

1 reference

Medical hazards of obesity

16 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

The influence of obesity on health (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Obesity and osteoarthritis of the knee: evidence from the National Health and Nutrition Examination Survey (NHANES I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Current estimates of the economic cost of obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Obesity, health services use, and health care costs among members of a health maintenance organization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Lifetime Health and Economic Consequences of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Body mass index and future healthcare costs: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Relationship between modifiable health risks and short-term health care charges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Economic costs of obesity and inactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Pharmaceutical cost savings of treating obesity with weight loss medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Pharmacologic induction of weight loss to treat type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Hypocaloric diet and antihypertensive drug treatment. A randomized controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Gastric surgery in morbid obesity. Outcome in patients aged 55 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Differentiated long-term effects of intentional weight loss on diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Obesity: adverse effects on health and longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

The 25-year health care costs of women who remain overweight after 40 years of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Social and economic effects of body weight in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

The cost of obesity: the US perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

The effect of gastric bypass surgery on hypertension in morbidly obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Lifetime health and economic benefits of weight loss among obese persons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Estimated economic costs of obesity to U.S. business

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Sick leave and disability pension before and after treatment for obesity: a report from the Swedish Obese Subjects (SOS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

Obesity and absenteeism: an epidemiologic study of 10,825 employed adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.191

31 March 2020

Identifiers

DOI

10.1038/OBY.2002.191

1 reference

16 June 2017

1 reference

PubMed ID

12446860